e-Newsletter | March / April 2021
Black Men Have Better Outcomes with
Immunotherapy Treatments for Prostate Cancer
Certain studies show greater prostate cancer survival benefits with immunotherapies for Black men compared to White men. A new Northwestern Medicine study has discovered what appears to be the reason. The findings, published in Nature Communications could lead to immune-based precision medicine treatment for men of all races.

In this study, scientists showed tumors from men of African ancestry have an increased proportion of a special immune cell compared to the tumors of white men. A research team led by Edward Schaeffer, MD, PhD, Chair of the Department of Urology at Northwestern University, identified these cells as potential drivers of prostate cancer immune-responsiveness.

This study supports the findings of a registry of men who were treated with PROVENGE (Sipuleucel-T), the first FDA approved prostate cancer immunotherapy treatment. The PROCEED registry study showed that Black men had significantly better survival benefits than white men.
Clinical Trial Opportunities
There are a number of prostate cancer immunotherapy clinical trials that are now being conducted. PHEN encourages Black patients to consider these trials as treatment options which could offer increased benefits. In addition, these trials may provide further data supporting the benefits of immunotherapy treatment for the population most impacted by prostate cancer.
For more clinical trials Information visit:
From initial diagnosis and all along a prostate cancer journey,
PHENPath.com supports patients in making informed and
shared-decisions with their doctors.

PHENPath.com Webinar
Wednesday, April 28th, 2021, at 6 pm ET

A Presentation and Patient Roundtable Discussion

A presentation demonstrating the use of PHENPath.com for men newly diagnosed with prostate cancer to identify their risk levels, and treatment options. A patient roundtable discussion will follow highlighting real-life experiences of patients when initially diagnosed with prostate cancer.
PHEN Sponsors